The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
Prenatal exposure to valproate is linked to increased risk of autism spectrum disorder, ADHD, lower IQ, and intellectual disability, especially at higher doses.
Behavioral activation significantly reduced suicidal ideation in women with perinatal depression, showing effectiveness whether delivered in-person or remotely by specialists and non-specialists.
Women with premenstrual mood disorders face significantly higher risk of suicidal ideation and behavior, highlighting the need for careful assessment and targeted prevention.
Weaning can be an emotionally charged transition, and for some women it may trigger depression. However, research on post-weaning depression is relatively sparse.
This study uncovers how trauma, isolation, loss of identity, and lack of support can overlap and amplify each other, deepening despair and driving suicide risk among women in the perinatal period.
Precocious puberty, particularly central precocious puberty (CPP), is increasingly common and is associated with a higher risk of long-term psychiatric disorders.
The relationship between breastfeeding and postpartum depression is complex and bidirectional, with each influencing the other through biological, psychological, and social factors.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
